Clinical Scorecard: Innovative Therapies in the nAMD Pipeline: What’s Coming Next?
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular age-related macular degeneration (nAMD) |
| Key Mechanisms | Targeting VEGF and complementary pathways including VEGF-C/D, FGF, IL-6, Ang-2, and Tie2; tyrosine kinase inhibition |
| Target Population | Patients with neovascular age-related macular degeneration |
| Care Setting | Ophthalmology clinics and specialized retinal care centers |
Key Highlights
- Next-generation biologics and gene therapies aim to extend durability and reduce treatment burden in nAMD.
- Multitargeted therapies modulate multiple angiogenesis, inflammation, and vascular stabilization pathways beyond VEGF inhibition.
- Tyrosine kinase inhibitors delivered via novel sustained-release systems show promising efficacy and safety in clinical trials.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of nAMD remains based on clinical examination and imaging to identify neovascular activity.
Management
- Current standard therapies include intravitreal anti-VEGF agents such as aflibercept.
- Emerging therapies include multitarget biologics (e.g., faricimab, tarcocimab tedromer) and gene therapies aiming for extended dosing intervals.
- Tyrosine kinase inhibitors (e.g., Axpaxli, CLS-AX, Duravyu) are under investigation for sustained delivery and improved outcomes.
Monitoring & Follow-up
- Visual acuity and retinal anatomy should be regularly monitored to assess treatment response and adjust dosing intervals.
Risks
- Potential risks include adverse events related to intravitreal injections and novel delivery systems; safety profiles are being evaluated in ongoing trials.
Patient & Prescribing Data
Treatment-naïve and previously treated patients with nAMD
Next-generation agents have demonstrated noninferior or superior visual acuity gains compared to aflibercept, with potential for reduced injection frequency and treatment burden.
Clinical Best Practices
- Consider emerging multitarget therapies for patients requiring extended durability beyond current anti-VEGF monotherapies.
- Monitor patients closely for efficacy and safety when using investigational agents or novel delivery systems.
- Stay updated on clinical trial outcomes to inform integration of new therapies into practice.
References
- Eylea HD (aflibercept 8 mg) efficacy in nAMD
- Faricimab (Vabysmo) clinical data
- DAYLIGHT trial of tarcocimab tedromer
- RC28-E phase 1b trial results
- SOL-1 phase 3 trial of Axpaxli
- OASIS phase 1/2a trial of CLS-AX
- DAVIO phase 1 and 2 trials of Duravyu
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.